| Literature DB >> 34401998 |
Dan Wang1,2, Xianlong Huang1,2, Lu Yan1,2, Luoqi Zhou1,2, Chang Yan1,2, Jinhu Wu1,2, Zhengding Su1,2, Yongqi Huang3,4.
Abstract
Tau is a microtubule-associated protein that is mainly expressed in central and peripheral nerve systems. Tau binds to tubulin and regulates assembly and stabilization of microtubule, thus playing a critical role in neuron morphology, axon development and navigation. Tau is highly stable under normal conditions; however, there are several factors that can induce or promote aggregation of tau, forming neurofibrillary tangles. Neurofibrillary tangles are toxic to neurons, which may be related to a series of neurodegenerative diseases including Alzheimer's disease. Thus, tau is widely accepted as an important therapeutic target for neurodegenerative diseases. While the monomeric structure of tau is highly disordered, the aggregate structure of tau is formed by closed packing of β-stands. Studies on the structure of tau and the structural transition mechanism provide valuable information on the occurrence, development, and therapy of tauopathies. In this review, we summarize recent progress on the structural investigation of tau and based on which we discuss aggregation inhibitor design.Entities:
Keywords: Drug design; Fibril structure; Neurodegenerative diseases; Protein aggregation; Tauopathies
Mesh:
Substances:
Year: 2021 PMID: 34401998 DOI: 10.1007/s10930-021-10017-6
Source DB: PubMed Journal: Protein J ISSN: 1572-3887 Impact factor: 2.371